Chapter 32: Managing Immune Deficiency Disorders

Managing Immune Deficiency Disorders details the management of patients grappling with both primary and acquired immune deficiency disorders, utilizing the nursing process as a foundational framework for patient care. It initially addresses Primary Immune Deficiency Diseases (PIDDs), which are rare, inherited genetic conditions often presenting in infancy with recurrent, persistent, or unusual infections that impair the immune system. Management strategies for PIDDs include hematopoietic stem cell transplantation (HSCT) as a curative option, along with pharmacologic therapies such as prophylactic antimicrobials and regular Immunoglobulin (Ig) replacement therapy, administered either intravenously (IVIG) or subcutaneously (SCIG). Nurses provide meticulous infection control, especially for neutropenic patients, and educate patients and caregivers on medication administration, Ig therapy, and home infection prevention. The chapter then transitions to Acquired Immune Deficiency, focusing heavily on Human Immune Deficiency Virus (HIV) infection and Acquired Immune Deficiency Syndrome (AIDS), classifying HIV as a chronic global public health concern. Pathophysiologically, HIV is identified as a retrovirus, specifically HIV-1, which carries RNA and targets CD4-positive T-lymphocytes. The HIV life cycle involves seven distinct stages—including binding, fusion, reverse transcription, and integration—which are targeted by various classes of Antiretroviral Therapy (ART) drugs, such as nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs). HIV infection is staged based on CD4+ T-cell counts, with Stage 3 representing AIDS, defined by a count below 200 cells/mm3 or the presence of a stage-3-defining opportunistic illness like Kaposi sarcoma or Pneumocystis pneumonia (PCP). Laboratory markers, including CD4+ T-cell count and plasma HIV RNA (viral load), are vital for staging and predicting disease prognosis, as a lower viral set point correlates with longer survival. Modern treatment strongly recommends ART for all HIV-infected individuals to maximally suppress the viral load, restore immune function, and prevent transmission. Adherence to combination ART regimens is paramount to prevent drug resistance and treatment failure, though challenges exist due to complex dosing schedules, severe side effects (like fat redistribution syndrome or lipodystrophy, hepatotoxicity, and nephrotoxicity), and psychosocial barriers such as stigma and depression. Prevention strategies are key, including behavioral interventions, pre-exposure prophylaxis (PrEP) using daily medications, and post-exposure prophylaxis (PEP) for occupational or assault exposure. Clinical manifestations of advanced HIV/AIDS span multiple organ systems and include severe opportunistic infections, such as Mycobacterium avium complex (MAC) disease and Cryptococcal meningitis, along with oncologic complications like AIDS-related lymphomas. Neurologic disorders like HIV-associated neurocognitive disorder (HAND) and peripheral neuropathy are also significant concerns. Nursing management of the AIDS patient centers on optimizing nutritional status, managing infectious processes, controlling symptoms like chronic diarrhea and pain, addressing psychosocial needs related to isolation and grief, and meticulously monitoring for medication adverse effects and the development of immune reconstitution inflammatory syndrome (IRIS), which can occur after ART initiation. Ethical considerations, particularly regarding patient confidentiality and addressing professional discomfort with stigmatized behaviors, are also discussed as core components of nursing responsibility.